Long term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era

C Cappelli, J Grill, M Raquin, A Pierre-Kahn, A Lellouch-Tubiana, M-J Terrier-Lacombe, J-L Habrand, D Couanet, R Brauner, D Rodriguez, O Hartmann, C Kalifa

Aim—To analyse the long term results of conservative management with radiotherapy in patients with optic pathway tumours.

Design—All 69 patients were symptomatic at diagnosis and most neoplasms involved the optic chiasm and hypothalamus.

Results—At 10 years, overall survival and progression free survival were 83% and 65.5%, respectively. After radiotherapy, vision improved in 18 patients and remained stable in 29 other patients. Cerebrovascular complications occurred in nine of 53 patients treated with radiotherapy after a median interval of two and a half years. These complications were five times more frequent in patients with neurofibromatosis type 1 (NF1). Severe intellectual disabilities were present in 18 children, most of whom underwent irradiation at a very young age (median age, 4 years).

Implications—Radiotherapy is a valuable treatment in terms of tumour response, visual outcome, and progression free survival. However, in young children and in patients with NF1, major sequelae are encountered and new treatment strategies should be proposed for these patients.

Keywords: optic pathway tumours, neurofibromatosis type 1; radiotherapy; long term follow up

Optic pathway tumours account for 5% of childhood intracranial tumours.1 Although these tumours are usually low grade astrocytomas, their natural history can be extremely erratic, ranging from long term stabilisation to progressive visual and neurological deterioration, culminating in death.2 Some patients might even present with metastasis at diagnosis2 or during the course of their disease,3 as demonstrated by sophisticated radiological techniques, such as magnetic resonance imaging (MRI). Because of this erratic behaviour, there is no consensus about the most appropriate management for these tumours.2,4 Surgery might be considered the best treatment for an optic nerve tumour of a blind eye, but chiasmatic and hypothalamic disease might require a totally different approach. With radiotherapy alone, or combined with surgery, progression free survival rates can attain 90% at five years.5,6 Moreover, most of the patients will benefit from radiotherapy for the preservation of visual function and acuity.6,7 However, survival rates decrease over time as a result of late relapses or complications.2,8 In recent years, chemotherapy has emerged as an interesting therapeutic tool for the management of optic pathway gliomas.9-14 The respective role and toxicity of these treatments need to be evaluated carefully before guidelines can be proposed. To clarify the usefulness and drawbacks of radiotherapy, we reviewed a large series of children treated in our institution before the chemotherapy era and after the availability of computed tomography (CT). Our study spans a 12 year period between 1980 and 1992.

Patients and methods

Patients
All children treated for an optic pathway tumour after 1980 at the Institut Gustave Roussy were enrolled in the study provided that their initial treatment did not include chemotherapy. After review, 69 patients were included. Six children were excluded because they had received chemotherapy before radiation or because of insufficient radiological documents. All patients were referred to our institute for complementary treatment of either progressive or life threatening tumours. Clinical data were obtained from the patients’ files. Ophthalmological evaluation included a fundus examination, visual field assessment, and measurement of visual acuity. Endocrinological evaluation was performed at various stages of the treatment either before or after radiotherapy and included standard procedures described elsewhere.15 Neurofibromatosis type 1 (NF1) was diagnosed either initially or during the course of the disease using standard clinical criteria.16 CT scans or MRI of the tumour were mandatory at diagnosis and at follow up. Children were included in this review regardless of the extent of the optic pathway tumour, which was classified by involved site according to Dodge classification: type I, a single optic nerve alone; type II, the optic chiasm and one or two optic nerves; type III, involvement of the hypothalamic or adjacent structures.17

EVALUATION OF RESPONSE
Response to radiotherapy was evaluated clinically and by ophthalmological examination, and radiologically by repeated CT scans or MRI. Radiological classification of responses followed International Society of Pediatric Oncology (SIOP) guidelines.18

Department of Pediatrics, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif, Cedex, France
C Cappelli
J Grill
M Raquin
O Hartmann
C Kalifa

Department of Pathology, Gustave Roussy Institute, M-J Terrier-Lacombe

Department of Radiation Therapy, Gustave Roussy Institute, J-L Habrand

Department of Radiology, Gustave Roussy Institute, D Couanet

Department of Neurosurgery, Hôpital Necker-Enfants Maladies, 75015 Paris, France
A Pierre-Kahn

Department of Pathology, Hôpital Necker-Enfants Maladies
A Lellouch-Tubiana

Department of Endocrinology, Hôpital Necker-Enfants Maladies
R Brauner

Department of Neuropediatrics, Hôpital Saint-Vincent de Paul, 75674 Paris Cedex 14, France
D Rodriguez

Correspondence to: Dr Grill.
e-mail: jgrill@grfr
Accepted 8 May 1998
Long term follow up of patients treated for optic pathway tumours

335

... Thirty four of 41 children with deficit(s) completely normal ophthalmological examination. Only three children had a visual acuity determination, visual field, and fundus examination. Forty four patients were investigated fully, with and visual outcome.

Ophthalmological evaluation at diagnosis and visual outcome

Forty four patients were investigated fully, with visual acuity determination, visual field, and fundus examination. Only three children had a completely normal ophthalmological examination. Thirty four of 41 children with deficit(s) had abnormal findings for both visual acuity, visual fields, and fundus. An abnormal visual field was present in all of the 41 children with a visual deficit except for one. Data on visual outcome were available for 62 patients. Four of the six patients who were blind at the time of diagnosis experienced no improvement, one had significant improvement, and one has been lost to follow up. Overall, 18 patients with initial visual defects had improved visual function after radiotherapy and 29 patients remained stable after treatment. Among nine patients with normal vision at diagnosis, six maintained normal vision without treatment and three maintained vision after radiotherapy. Thus, regardless of their initial visual capacity, 18 patients improved after radiotherapy; 29 patients remained stable with radiotherapy and eight without treatment; seven had visual deterioration, despite radiotherapy, even without a significant increase in tumour burden.

Survival

The mean (SD) follow up of the patients included in this study was 7.6 (4.6) years, with a median follow up of 7 years. Initial treatment was surveillance in 16, radiotherapy in 39, and surgery in 14 patients. Overall survival of...
symptomatic patients with optic pathway gliomas continued to decrease after the fifth year of follow up, reaching 74% at 15 years (fig 2).

Overall and event free survival were better in children with NF1 than in the other children, but the difference was not significant (figs 3 and 4). The outcome of the patients according to the initial treatment is described in a flow diagram (fig 5). Among the six children with tumour confined to one optic nerve and with residual vision, three received irradiation initially and are long term survivors, and we decided on strict surveillance for the other three. Only one of them experienced progressive disease for which he received irradiation and this treatment has permitted long term progression free survival. Causes of death were progressive disease in seven, a secondary tumour in two, and a stroke in one patient. Of the two patients who died of a second tumour, one developed a Ewing's sarcoma outside the radiation field and the other had a progressive glioblastoma multiforme that had arisen inside the radiation field, 6.5 years and 14 years, respectively, after the diagnosis of the optic pathway tumour. The latter patient did not have NF1 and the glioblastoma was not secondary to the transformation of his optic pathway tumour.

CEREBROVASCULAR COMPLICATIONS
Nine patients experienced cerebrovascular complications during follow up. The mean age of these patients at irradiation (5 years; range, 2–8 years) was not different from the mean age of the whole population. All of them received radiotherapy with median doses of 54 Gy. Thus, nine of 54 of the patients treated with irradiation experienced a cerebrovascular complication during follow up. Eight of them had NF1. Therefore, nine of 31 of the NF1 patients treated with irradiation experienced such a complication compared with only one of 22 patients without NF1. There was a median interval of 2.5 years between radiotherapy and the development of cerebrovascular complications (range, 6 months to 6 years). All but one were symptomatic. In this latter patient, a small ischaemic lesion was discovered in the internal capsule at reassessment of follow up scans. Two other patients had a transient ischaemic attack. Six patients experienced a stroke followed by hemiplegia. In three patients, angiography has been performed and showed stenosis of the carotid arteries and moyamoya vessels. One patient died of complications shortly after the stroke.

INTELLECTUAL OUTCOME
At the time of the last visit, 33 children had achieved a normal scholastic level commensurate with their age category (that is, < 2 years behind), 10 of them attending a special school for blind children. Eighteen patients experienced major scholastic failure, 12 of them being placed in an institution for mentally retarded children. All of these severely disabled
Long term follow up of patients treated for optic pathway tumours

<table>
<thead>
<tr>
<th>Group</th>
<th>Outcome</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surveillance</td>
<td>DOD (n = 2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SD (n = 8)*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PD (n = 6)</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>DOD (n = 3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DOC (n = 3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AWD (n = 3)</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>PD (n = 9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>APF (n = 45)†</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 lost of follow up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DOD (n = 2)</td>
<td></td>
</tr>
</tbody>
</table>

Figure 5. Outcome according to the initial treatment; number of patients is given for each subgroup. The 54 patients treated with radiotherapy were treated either initially (n = 39), after surgery (n = 9) or after initial surveillance (n = 6). *Sixteen patients (including 11 patients with neurofibromatosis type 1) were followed up initially without treatment; disease remained stable in eight of these patients during long term follow up (median, 4.5 years; range, 2–11); seven out of these eight had NF1. †Radiation doses ranged between 50 and 55 Gy in all the patients but two, who received doses lower than 40 Gy and subsequently relapsed. Forty five of the 54 patients treated with radiotherapy are alive without progression with a median follow up of 7 years (range, 5 months to 15 years).

Discussion

Treatment regimens for optic pathway tumours are still a matter of debate. To clarify the effectiveness of conservative surgery and radiotherapy, we chose to analyse retrospectively a large number of patients treated during an era when modern imaging was available yet the current strategy of using chemotherapy had not been implemented. In this study, radiotherapy preceded or not by conservative surgery is shown to be a valuable treatment in terms of tumour control and visual preservation. However, in young children and in those with NF1, this approach should be reconsidered because of severe late effects. Once the tumour has invaded the chiasm, the optic tracts, or the diencephalon, surgical resection is generally no longer feasible. When confronted with clear cut tumour progression and visual impairment, radiotherapy has, until recently, been considered the standard treatment. Because most of the patients in our series presented with Dodge type II or III tumours, our treatment strategies were either based on surveillance or radiotherapy preceded by conservative surgery or not. The study and follow up of this cohort has helped us to define long term survival and morbidity for children with symptomatic optic pathway tumours. In our series, five year and 10 year overall survival rates were 91% and 83%, respectively. Five year overall survival for patients with optic pathway tumours is ∼85% in most studies, but this figure continues to decline with time. Six late deaths occurred after the fifth year from diagnosis (two second tumours, three late relapses, and one complication related death). This emphasises the need for prolonged follow up for proper evaluation of treatment strategies in these patients. There is a dearth of consistent information regarding the impact of radiation treatment on visual outcome. In addition, the reporting of visual outcome after radiotherapy has been largely unreliable because very young children are frequently considered un evaluable. However, our study and similar reports consider radiotherapy beneficial to visual function. Only a small proportion of children experienced a worsening of their visual status but almost a third experienced an improvement.

The fact that all the patients in our study were symptomatic with tumour progression at diagnosis led us to consider stable disease (both radiologically and clinically) as a yardstick of successful radiotherapy. However, among the 16 children who received no treatment, disease did not progress further during follow up in half of them. Thus, for some selected patients, aggressive treatment might legitimately be postponed, even when disease is symptomatic. Although a more indolent behaviour of optic pathway glioma has been suggested in patients with NF1, we cannot recommend surveillance as a rule for all patients with NF1 and optic pathway glioma. Because all of the children were followed up by CT scans and/or MRI, the radiological response to radiotherapy could be determined precisely and meticulously. More than half of the children who underwent irradiation achieved a significant radiological response, which became evident after the sixth month following radiotherapy.

Only a few studies (with a small number of patients) have reported the effect of radiotherapy on tumour size; response rates were similar to those obtained in our study. When the impact of chemotherapy or radiotherapy on optic pathway glioma is analysed in further trials, it should be borne in mind that radiological responses might be delayed and that children with stable disease at the end of radiotherapy might be cured, as was the case for almost half of our patients. In comparison, the best response rate with chemotherapy in newly diagnosed young patients reaches 57% of significant radiological responses with carboplatin and vincristine. The relapse rate is low in patients treated with radiotherapy, as confirmed in this large series. Indeed, relapse is seen in 10–15% of patients who have undergone radiotherapy. However, late tumour recurrences might be encountered after the fifth year, as was the case in four of our patients.

Recently, the presence of NF1 has been shown to be associated significantly with a lower risk of first relapse. This aspect could not be explored in our patients, because of the low relapse rate after radiotherapy. Moreover, as some children with NF1 did not receive radiotherapy initially and subsequently relapsed, we can assume that, once treated with radiotherapy, relapse free survival would also have been significantly higher in these patients. However, overall survival was not different for...
children with NF1 because many of them experienced treatment related adverse effects or second tumours.

Complications currently reported in children receiving radiotherapy for optic pathway tumours concern impaired cognitive development and hormone deficiency. Among the 47 children who had a complete endocrinological evaluation after radiotherapy, only three had a normal endocrine status. Of all the pituitary hormones, growth hormone was the most sensitive to radiotherapy because deficiency of this hormone was seen in 37 of the 44 patients with hormone deficiency. In agreement with other reports, the intellectual outcome was poor for those patients in our series who received radiotherapy, especially before the age of 4 years. This emphasises the need for careful neuropsychological surveillance in children receiving radiotherapy for optic pathway gliomas, so that an adapted rehabilitation programme can be planned. There are now increasing case reports of cerebrovascular complications after radiotherapy for optic pathway glioma. Among 40 patients with radiation related cerebral occlusive disease reported elsewhere, 16 received radiotherapy for optic pathway gliomas. However, the frequency of this complication was not determined precisely in a large series of patients submitted to radiotherapy for optic pathway glioma. To date (and this figure may increase with prolonged follow up), almost a fifth of the children have experienced complications of radiation induced vasculopathy. All but one had NF1. Underlying vascular abnormalities in these patients might exacerbate the risk of such complications, as suggested in one report. With more patients with NF1 being treated with irradiation, our study shows that this complication is five times more frequent in patients with NF1. Cerebrovascular complications occurred early during follow up in our study. However, as reported by Bitzer et al, this complication can sometimes occur late after irradiation—that is, 10 years after treatment. Because of the high rate of radiation related complications, we propose delaying radiotherapy in patients with NF1 if possible, and suggest that other therapeutic options should be considered first. If irradiation is performed, longitudinal follow up of the cerebral vessels should be included in the surveillance from the first year after treatment.

Conclusion

For progressive optic pathway gliomas involving the optic chiasm or diencephalon, radiotherapy with or without conservative surgery is a valuable treatment strategy in terms of tumour response, visual outcome, and progression free survival. However, treatment related complications can be unacceptable, especially in patients with NF1 who are at risk for radiation induced cerebral vasculopathy. Therefore, radiotherapy is no longer recommended as first line treatment in children younger than 5 years or those suffering from NF1. The role of chemotherapy with or without conservative surgery should be explored in these patients at higher risk for radiation related complications.

We thank Ms Lorna Saint-Angé for editing the manuscript.

Long term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era

C Cappelli, J Grill, M Raquin, A Pierre-Kahn, A Lellouch-Tubiana, M-J Terrier-Lacombe, J-L Habrand, D Couanet, R Brauner, D Rodriguez, O Hartmann and C Kalifa

Arch Dis Child 1998 79: 334-338
doi: 10.1136/adc.79.4.334

Updated information and services can be found at:
http://adc.bmj.com/content/79/4/334

These include:
References
This article cites 25 articles, 1 of which you can access for free at:
http://adc.bmj.com/content/79/4/334#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Oncology (777)
- Clinical diagnostic tests (1133)
- Radiology (976)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/